Drug Profile

Doxorubicin intratumoural - LIDDS

Alternative Names: NZ DOX

Latest Information Update: 01 Aug 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator LIDDS
Class Anthracyclines; Antineoplastics; Cytostatic antibiotics; Doxorubicins; Small molecules
Mechanism of Action DNA intercalators; Type II DNA topoisomerase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

No development reported Solid tumours

Most Recent Events

08 Jul 2022 LIDDS has patent protection for NanoZolid® production process in Israel
07 Jun 2022 LIDDS has patent protection for NanoZolid® production process in Japan, South Korea, China, Russia, Australia, India, South Africa and Singapore
28 Dec 2021 No recent reports of development identified for research development in Solid-tumours in Sweden (Intratumoural)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com